History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress

Drug and Alcohol Dependence

Volumn 142, Issue , 2014, Pages 262-268

  Durazzo, Timothy C ^a,b   Mattsson, Niklas ^a,b,c   Weiner, Michael W ^a,b   Korecka, Magdalena ^d   Trojanowski, John Q ^d   Shaw, Leslie M ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cerebrospinal fluid; Cigarette smoking; Elder adults; Hippocampus; Isoprostanes; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; ISOPROSTANE DERIVATIVE; TRIACYLGLYCEROL;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID BRAIN LEVEL; MALE; MEDICAL HISTORY; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SMOKING HABIT; TANDEM MASS SPECTROMETRY; CEREBROSPINAL FLUID; HIPPOCAMPUS; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; F2-ISOPROSTANES; FEMALE; HIPPOCAMPUS; HUMANS; MALE; ORGAN SIZE; OXIDATIVE STRESS; SMOKING;

EID: 84905587141     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.06.030     Document Type: Article

References (83)

1. Ambrose J.A., Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am Coll. Cardiol. 2004, 43:1731-1737.
2. Anbarasi K., Vani G., Balakrishna K., Devi C.S. Effect of bacoside A on membrane-bound ATPases in the brain of rats exposed to cigarette smoke. J. Biochem. Mol. Toxicol. 2005, 19:59-65.
3. Anbarasi K., Vani G., Balakrishna K., Devi C.S. Effect of bacoside A on brain antioxidant status in cigarette smoke exposed rats. Life Sci. 2006, 78:1378-1384.
4. Azizian A., Monterosso J., O'Neill J., London E.D. Magnetic resonance imaging studies of cigarette smoking. Nicotine Psychopharmacology 2009, 113-143. Springer-Verlag Berlin Heidelberg, Berlin Heidelberg. J.E. Henningfield, E. Calvento, S. Pogun (Eds.).
5. Barnes D.E., Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011, 10:819-828.
6. Bloomer R.J. Decreased blood antioxidant capacity and increased lipid peroxidation in young cigarette smokers compared to nonsmokers: impact of dietary intake. Nutr. J. 2007, 6:39.
7. Butterfield D.A., Swomley A.M., Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal 2013, 19:823-835.
8. Cataldo J.K., Prochaska J.J., Glantz S.A. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J. Alzheimer's Dis. 2010, 19:465-480.
9. Chalela J.A., Wolf R.L., Maldjian J.A., Kasner S.E. MRI identification of early white matter injury in anoxic-ischemic encephalopathy. Neurology 2001, 56:481-485.
10. Chang C.C., Zhao Y., Lee C.W., Ganguli M. Smoking, death, and Alzheimer disease: a case of competing risks. Alzheimer Dis. Assoc. Disord. 2012, 26:300-306.
11. Chiang G.C., Insel P.S., Tosun D., Schuff N., Truran-Sacrey D., Raptentsetsang S.T., Jack C.R., Aisen P.S., Petersen R.C., Weiner M.W. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology 2010, 75:1976-1981.
12. Cracowski J.L., Durand T., Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002, 23:360-366.
13. Crews F.T., Bechara R., Brown L.A., Guidot D.M., Mandrekar P., Oak S., Qin L., Szabo G., Wheeler M., Zou J. Cytokines and alcohol. Alcohol. Clin. Exp. Res. 2006, 30:720-730.
14. Crews F.T., Nixon K. Mechanisms of neurodegeneration and regeneration in alcoholism. Alcohol Alcohol. 2009, 44:115-127.
15. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
16. Dube S.R., McClave A., James C., Caraballo R., Kaufmann R., Pechacek T.F. Office on Smoking and Health. National Center for Chronic Disease Prevention and Health Promotion. CDC. Vital signs: current cigarette smoking among adults aged ≥ 18 years --- United States in 2009. MMWR 2010, 59:1135-1140.
17. Durazzo T.C., Insel P.S., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative Greater regional brain atrophy rate in healthy elders with a history of cigarette smoking. Alzheimer's Dement. 2012, 8:513-519.
18. Durazzo, T.C., Mattsson, N., Weiner, M.W. ,The Alzheimer's Disease Neuroimaging Initiative. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers's Dement. 10, 2014a, S122-S145.
19. Durazzo T.C., Meyerhoff D.J., Nixon S.J. Interactive effects of chronic cigarette smoking and age on hippocampal volumes. Drug Alcohol Depend. 2013, 133:704-711.
20. Durazzo T.C., Meyerhoff D.J. Neurobiological and neurocognitive effects of chronic cigarette smoking and alcoholism. Front. Biosci. 2007, 12:4079-4100.
21. Durazzo T.C., Meyerhoff D.J., Nixon S.J. Chronic cigarette smoking: implications for neurocognition and brain neurobiology. Int. J. Environ. Res. Public Health 2010, 7:3760-3791.
22. Durazzo T.C., Mon A., Pennington D., Abe C., Gazdzinski S., Meyerhoff D.J. Interactive effects of chronic cigarette smoking and age on brain volumes in controls and alcohol-dependent individuals in early abstinence. Addict. Biol. 2014, 19:132-143.
23. Enciu A.M., Gherghiceanu M., Popescu B.O. Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxidative Med. Cell Longev. 2013, (Article ID: 297512; 〈http://dx.doi.org/10.1155/2013/297512〉).
24. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. USA 2000, 97:11050-11055.
25. Fischl B., Destrieux C., Halgren E., Segonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatic parcellation of the human cerebral cortex. Cereb. Cortex 2004, 14:11-22.
26. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis II: inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
27. Fowles J., Bates M., Noiton D. The Chemical Constituents in Cigarettes and Cigarette Smoke: Priorities for Harm Reduction 2000, 1-65. Epidemiology and Toxicology Group, Institute of Environmental Science and Research Ltd., Porirua, New Zealand, http://www.health.govt.nz/publication/chemical-constituents-cigarettes-and-cigarette-smoke-priorities-harm-reduction.
28. Galasko D., Montine T.J. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark. Med. 2010, 4:27-36.
29. Gill R., Tsung A., Billiar T. Linking oxidative stress to inflammation: toll-like receptors. Free Radic. Biol. Med. 2010, 48:1121-1132.
30. Giunta B., Deng J., Jin J., Sadic E., Rum S., Zhou H., Sanberg P., Tan J. Evaluation of how cigarette smoke is a direct risk factor for Alzheimer's disease. Technol. Innov. 2012, 14:39-48.
31. Guerri C., Pascual M. Mechanisms involved in the neurotoxic, cognitive, and neurobehavioral effects of alcohol consumption during adolescence. Alcohol 2010, 44:15-26.
32. Gunter, J.L., Bernstein, M.A., Borowski, B., Felmlee, J.P., Blezek, D., Mallozzi, R., 2006. Validation testing of the MRI calibration phantom for the Alzheimer's disease neuroimaging initiative study. In: Proceedings of the ISMRM 14th Scientific Meeting and Exhibition.
33. Haight T.J., Landau S.M., Carmichael O., Schwarz C., Decarli C., Jagust W.J. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol. 2013, 70:1039-1045.
34. Harman S.M., Liang L., Tsitouras P.D., Gucciardo F., Heward C.B., Reaven P.D., Ping W., Ahmed A., Cutler R.G. Urinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokers. Free Radic. Biol. Med. 2003, 35:1301-1309.
35. Haschke M., Zhang Y.L., Kahle C., Klawitter J., Korecka M., Shaw L.M., Christians U. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin. Chem. 2007, 53:489-497.
36. Haustein K.O. Smoking tobacco, microcirculatory changes and the role of nicotine. Int. J. Clin. Pharmacol. Ther. 1999, 37:76-85.
37. Helmersson J., Larsson A., Vessby B., Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005, 181:201-207.
38. Ho Y.S., Yang X., Yeung S.C., Chiu K., Lau C.F., Tsang A.W., Mak J.C., Chang R.C. Cigarette smoking accelerated brain aging and induced pre-Alzheimer-like neuropathology in rats. PLoS One 2012, doi: 10.1371/journal.pone.0036752, http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0036752.
39. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J.L., Whitewell J., Ward C., Dale A.M., Felmlee J.P., et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 2008, 27:685-691.
40. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
41. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R.N., McAfee T., Peto R. 21st-century hazards of smoking and benefits of cessation in the United States. N. Engl. J. Med. 2013, 368:341-350.
42. Khandelwal P.J., Herman A.M., Moussa C.E. Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 2011, 238:1-11.
43. Khanna A., Guo M., Mehra M., Royal W. Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains. J. Neuroimmunol. 2013, 254:69-75.
44. Korecka M., Clark C.M., Lee V.M., Trojanowski J.Q., Shaw L.M. Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2010, 878:2209-2216.
45. Kovacic P. Unifying mechanism for addiction and toxicity of abused drugs with application to dopamine and glutamate mediators: electron transfer and reactive oxygen species. Med. Hypotheses 2005, 65:90-96.
46. Kuhn S., Romanowski A., Schilling C., Mobascher A., Warbrick T., Winterer G., Gallinat J. Brain grey matter deficits in smokers: focus on the cerebellum. Brain Struct. Funct. 2012, 217:517-522.
47. Kuhn S., Schubert F., Gallinat J. Reduced thickness of medial orbitofrontal cortex in smokers. Biol. Psychiatry 2010, 68:1061-1065.
48. Kukull W.A. The association between smoking and Alzheimer's disease: effects of study design and bias. Biol. Psychiatry 2001, 49:194-199.
49. Milne G.L., Musiek E.S., Morrow J.D. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005, 10(Suppl 1):S10-S23.
50. Montine T.J., Peskind E.R., Quinn J.F., Wilson A.M., Montine K.S., Galasko D. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromol. Med. 2011, 13:37-43.
51. Moriarty S.E., Shah J.H., Lynn M., Jiang S., Openo K., Jones D.P., Sternberg P. Oxidation of glutathione and cysteine in human plasma associated with smoking. Free Radic. Biol. Med. 2003, 35:1582-1588.
52. Mueller S.G., Trabesinger A.H., Boesiger P., Wieser H.G. Brain glutathione levels in patients with epilepsy measured by in vivo (1)H-MRS. Neurology 2001, 57:1422-1427.
53. Mueller S.G., Weiner M.W. Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. Hippocampus 2009, 19:558-564.
54. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin. N. Am. 2005, 15(869-877):xi-xii.
55. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimer's Dement. 2005, 1:55-66.
56. O'Dwyer L., Lamberton F., Matura S., Tanner C., Scheibe M., Miller J., Rujescu D., Prvulovic D., Hampel H. Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One 2012, http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0048895#pone-0048895-g002.
57. Perricone C., De Carolis C., Perricone R. Glutathione: a key player in autoimmunity. Autoimmun. Rev. 2009, 8:697-701.
58. Peters R., Poulter R., Warner J., Beckett N., Burch L., Bulpitt C. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008, 8:36. 〈http://www.biomedcentral.com/1471-2318/8/36〉.
59. Pratico D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 2008, 201:8-16.
60. Pratico D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:930-933.
61. Rokach J., Kim S., Bellone S., Lawson J.A., Pratico D., Powell W.S., FitzGerald G.A. Total synthesis of isoprostanes: discovery and quantitation in biological systems. Chem. Phys. Lipids 2004, 128:35-56.
62. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., FitzGerald G.A. Nomenclature of isoprostanes: a proposal. Prostaglandins 1997, 54:853-873.
63. Rueff-Barroso C.R., Trajano E.T., Alves J.N., Paiva R.O., Lanzetti M., Pires K.M., Bezerra F.S., Sabia S., Elbaz A., Dugravot A., Head J., Shipley M., Hagger-Johnson G., Kivimaki M., Singh-Manoux A. Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study. Arch. Gen. Psychiatry 2012, 69:627-635.
64. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 2000, 267:4904-4911.
65. Seet R.C., Lee C.Y., Loke W.M., Huang S.H., Huang H., Looi W.F., Chew E.S., Quek A.M., Lim E.C., Halliwell B. Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress?. Free Radic. Biol. Med. 2011, 50:1787-1793.
66. Sharma A., Brody A. In vivo brain imaging of human exposure to nicotine and tobacco. Nicotine Psychopharmacology 2009, 145-171. Springer-Verlag Berlin Heidelberg. J.E. Henningfield, E. Calvento, S. Pogun (Eds.).
67. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413.
68. Sonnen J.A., Larson E.B., Gray S.L., Wilson A., Kohama S.G., Crane P.K., Breitner J.C., Montine T.J. Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann. Neurol. 2009, 65:226-229.
69. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012, 11:1006-1012.
70. Sutherland G.T., Chami B., Youssef P., Witting P.K. Oxidative stress in Alzheimer's disease: primary villain or physiological by-product?. Redox Rep. 2013, 18:134-141.
71. Swan G.E., Lessov-Schlaggar C.N. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol. Rev. 2007, 17:259-273.
72. Swerdlow R.H. Alzheimer's disease pathologic cascades: who comes first what drives what. Neurotox. Res. 2012, 22:182-194.
73. Talhout R., Schulz T., Florek E., van Benthem J., Wester P., Opperhuizen A. Hazardous compounds in tobacco smoke. Int. J. Environ. Res. Public Health 2011, 8:613-628.
74. Tyas S.L., White L.R., Petrovitch H., Webster Ross G., Foley D.J., Heimovitz H.K., Launer L.J. Mid-life smoking and late-life dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2003, 24:589-596.
75. Valavanidis A., Vlachogianni T., Fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int. J. Environ. Res. Public Health 2009, 6:445-462.
76. Voloboueva L.A., Giffard R.G. Inflammation, mitochondria, and the inhibition of adult neurogenesis. J. Neurosci. Res. 2011, 89:1989-1996.
77. Wagner M., Schulze-Rauschenbach S., Petrovsky N., Brinkmeyer J., von der Goltz C., Grunder G., Spreckelmeyer K.N., Wienker T., Diaz-Lacava A., Mobascher A., Dahmen N., Clepce M., et al. Neurocognitive impairments in non-deprived smokers-results from a population-based multi-center study on smoking-related behavior. Addict. Biol. 2013, 18:752-761.
78. Wang X., Michaelis E.K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2010, 2:12. 10.3389/fnagi.2010.00012.
79. Wannamethee S.G., Lowe G.D.O., Shaper A.G., Rumley A., Lennon L., Whincup P.H. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur. Heart J. 2005, 26:1765-1773.
80. Yan W., Byrd G.D., Ogden M.W. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J. Lipid Res. 2007, 48:1607-1617.
81. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., Geertjan Wesseling G., Wouters E.F.M. Systemic effects of smoking. Chest 2007, 131:1557-1566.
82. Yang Y.M., Liu G.T. Injury of mouse brain mitochondria induced by cigarette smoke extract and effect of vitamin C on it in vitro. Biomed. Environ. Sci. 2003, 16:256-266.
83. Yao Y., Zhukareva V., Sung S., Clark C.M., Rokach J., Lee V.M., Trojanowski J.Q., Pratico D. Enhanced brain levels of 8,12-iso-iPF(2alpha)-VI differentiate AD from frontotemporal dementia. Neurology 2003, 61:475-478.